Trump's executive order lacks specifics and raises questions on what can be accomplished, what will be challenged in court.

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed by Endpoints News.

I really thought today might be an easy day. I should have known better.

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose.

Peter Marks’ ouster comes at a time when the sector is already suffering through a years-long public markets slump.

Michael Lewis on Heather Stone of the Food and Drug Administration.

And a J&J lawsuit over biosimilars is the first shot in the war against PBM-backed pseudo-pharma companies

It's one of those drinking-from-a-firehose days

Plus a bit on how tariffs are going to worsen, not improve, the issues with generic meds in the United States. And Kennedy nears the end of the beginning.

Americans are divided over President-elect Trump's policies for lowering healthcare costs. Views vary by political affiliation, but by two to one, independents think the policies take the U.S. in the ...

The hornet was discovered in a corner of Washington State. Five years later, a massive mobilization has eliminated the invasive species, at least for now.

Share your videos with friends, family, and the world

A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's nomination as FDA chief has eased some worries, while Robert F. Kennedy Jr.'s ...

Plus an important corrective to the pharmacy-closure story from last week

And a breathless Reuters story suggests that industry thinks IRA fixes are in play during Trump 2.0

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals.

This Special Communication analyzes and compares development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment...

The data has some gaps -- as the state recognizes -- but it's still a fantastic resource for seeing how the program operates at a more granular level

And trying to catch up on everything from IP reform to 340B messaging